International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019

COVID-19-Core Outcomes Set (COS) Survey Investigators, Nicole Evangelidis, Allison Tong, Martin Howell, Armando Teixeira-Pinto, Julian H. Elliott, Luciano Cesar Azevedo, Andrew Bersten, Lilia Cervantes, Derek P. Chew, Sally Crowe, Ivor S. Douglas, Ella Flemyng, Peter Horby, Jaehee Lee, Eduardo Lorca, Deena Lynch, John C. Marshall, Anne McKenzie, Sangeeta MehtaMervyn Mer, Andrew Conway Morris, Saad Nseir, Pedro Povoa, Mark Reid, Yasser Sakr, Ning Shen, Alan R. Smyth, Tom Snelling, Giovanni F.M. Strippoli, Antoni Torres, Tari Turner, Steve Webb, Paula R. Williamson, Laila Woc-Colburn, Junhua Zhang, Amanda Baumgart, Sebastian Cabrera, Yeoungjee Cho, Tess Cooper, Chandana Guha, Emma Liu, Andrea Matus Gonzalez, Charlie McLeod, Patrizia Natale, Valeria Saglimbene, Andrea K. Viecelli, Jonathan C. Craig

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


OBJECTIVES: There are over 4,000 trials conducted in people with coronavirus disease 2019. However, the variability of outcomes and the omission of patient-centered outcomes may diminish the impact of these trials on decision-making. The aim of this study was to generate a consensus-based, prioritized list of outcomes for coronavirus disease 2019 trials. DESIGN: In an online survey conducted in English, Chinese, Italian, Portuguese, and Spanish languages, adults with coronavirus disease 2019, their family members, health professionals, and the general public rated the importance of outcomes using a 9-point Likert scale (7-9, critical importance) and completed a Best-Worst Scale to estimate relative importance. Participant comments were analyzed thematically. SETTING: International. SUBJECTS: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public, and health professionals (including clinicians, policy makers, regulators, funders, and researchers).None. MAIN RESULTS: In total, 9,289 participants from 111 countries (776 people with coronavirus disease 2019 or family members, 4,882 health professionals, and 3,631 members of the public) completed the survey. The four outcomes of highest priority for all three groups were: mortality, respiratory failure, pneumonia, and organ failure. Lung function, lung scarring, sepsis, shortness of breath, and oxygen level in the blood were common to the top 10 outcomes across all three groups (mean > 7.5, median ≥ 8, and > 70% of respondents rated the outcome as critically important). Patients/family members rated fatigue, anxiety, chest pain, muscle pain, gastrointestinal problems, and cardiovascular disease higher than health professionals. Four themes underpinned prioritization: fear of life-threatening, debilitating, and permanent consequences; addressing knowledge gaps; enabling preparedness and planning; and tolerable or infrequent outcomes. CONCLUSIONS: Life-threatening respiratory and other organ outcomes were consistently highly prioritized by all stakeholder groups. Patients/family members gave higher priority to many patient-reported outcomes compared with health professionals.

Original languageEnglish
Pages (from-to)1612-1621
Number of pages10
JournalCritical Care Medicine
Issue number11
Publication statusPublished - 1 Nov 2020
Externally publishedYes


Dive into the research topics of 'International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019'. Together they form a unique fingerprint.

Cite this